Αρχική World News Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with... World News Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer Από Ogkologos - 23 Απριλίου, 2025 927 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Get the Most out of Seasonal Fruits! 28 Δεκεμβρίου, 2020 EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel 28 Φεβρουαρίου, 2025 FDA Approves Avapritinib for Advanced Systemic Mastocytosis 17 Ιουνίου, 2021 Artist Tattoos Realistic Nipples On Breast Cancer Survivors Post-Mastectomy 13 Οκτωβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... At 3-Year Follow-Up Nivolumab Plus Chemotherapy Continued to Demonstrate OS Improvement... Taking on the RAS Challenge Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with...